Transparency and Disclosure

Transparency and Disclosure_DEV

Study Participant Engagement, Transparency, and Disclosure Services Synchrogenix provides expertise, services, and technology, not only to meet transparency and disclosure requirements, but also as a complement to our commitment to enhance engagement of study participants and the general public in drug development. Synchrogenix produces anonymized and redacted datasets and clinical documents; authors Informed Consent Forms […]

Read More
Topics:

Technology and Innovation_DEV

Leading Edge Systems Synchrogenix develops interoperable and innovative technologies that support our services and differentiate ourselves in the market. Additionally, Synchrogenix provides strategy and delivery capabilities to implement emerging technology solutions both internally and externally. Synchrogenix offers the following solutions: Open APIs Microservices Data abstraction/anonymization User interface/data visualization solutions Cryptographic services Blockchain technology Artificial intelligence […]

Read More
Topics:

Artificial Intelligence Software

Empowering Regulatory Sciences Artificial Intelligence (AI) technology is revolutionizing life sciences, and over the next decade, will continue to enable advancements at unprecedented rates. Through the use of AI technology, Synchrogenix has developed a solution in the area of regulatory and medical writing that truly meets the promise of automated authoring and is also the […]

Read More
Topics:

Transparency and Disclosure

Mitigating Risk and Ensuring Compliance As the issue of transparency and disclosure (T&D) of clinical trial information has grown in importance, so has the recognition that sharing clinical trial information is a key step toward increasing trust between the public and the industry. More importantly, increased transparency regarding data about ongoing research could spur new […]

Read More
Topics:

Synchrogenix ClinGenuity Redaction Management Solution (CRMS)

Synchrogenix’s unique AI engine, has created an engine that is built on natural language processing and recognition. Because of the power behind our unique AI, the engine can be configured to identify PPD and CCI the same way an individual would be trained on these definitions. The process of identifying and redacting sensitive information becomes automated and significantly more accurate.

Read More
Topics:

Strategic Regulatory Writing for Drug Development Success

Kelley Kendle

Happy New Year! The start of a new year brings the promise of new opportunities for growth—both personally and professionally. As the CEO for Synchrogenix, Certara’s regulatory writing consultancy, I’ve been thinking a lot lately about how changes in the regulatory writing landscape will shape the drug development process in 2015. It’s becoming more and more […]

Read More
Topics: Clinical Transparency & Disclosure, Regulatory & Medical Writing
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog